Activatable organic upconversion nanoprobe for bioimaging of monoamine oxidase B in Parkinson's disease

被引:3
|
作者
Zhang, Yuanyuan [1 ,3 ]
Wang, Jing [3 ]
Yi, Wanxiang [3 ]
Tiemuer, Aliya [3 ]
Yu, Hui [3 ]
Liu, Yi [2 ,3 ]
Su, Dan [1 ]
机构
[1] Hangzhou Med Coll, Dept Clin Med, Key Lab Drug Safety Evaluat & Res Zhejiang Prov, Hangzhou 310053, Peoples R China
[2] Nanjing Univ Posts & Telecommun, Inst Adv Mat IAM, Jiangsu Key Lab Biosensors, 9 Wenyuan Rd, Nanjing 210023, Peoples R China
[3] China Pharmaceut Univ, Sch Engn, Nanjing 211198, Peoples R China
基金
中国国家自然科学基金;
关键词
Frequency upconversion luminescence; Monoamine oxidase B; Near Infrared nanoprobes; Bio-imaging; Parkinson's disease; FLUORESCENT-PROBE; MAO-A; MICE; DESIGN;
D O I
10.1016/j.snb.2023.133880
中图分类号
O65 [分析化学];
学科分类号
070302 ; 081704 ;
摘要
Monoamine oxidase B (MAO-B) activity has been observed abnormally elevated in Parkinson's disease patients and can be used as a potential biomarker. Herein, we report an activatable frequency upconversion luminescence (FUCL) MAO-B nano-probe (NIR-MNP) capable of highly specific and real-time MAO-B imaging in biological samples. The turn-on FUCL effect is beneficial to obtaining high-quality imaging and penetrating tissue to achieve in vivo imaging, making it stand out from the existing probes. Moreover, we used NIR-MNP to confirm the role of MAO-B inhibitor in delaying Parkinson's disease (PD) progression in mouse PD models through bioimaging technique in vivo. Finally, our study may offer a visual way help researchers to gain further insight into the involvement of MAO-B in PD onset and progression in animals.
引用
收藏
页数:9
相关论文
共 50 条
  • [1] Monoamine oxidase B activatable red fluorescence probe for bioimaging in cells and zebrafish
    Yang, Zhengmin
    Zhong, Tiantian
    Mo, Qingyuan
    He, Jiman
    Chong, Jia
    Hu, Xianyun
    Zhao, Shulin
    Qin, Jiangke
    BIOORGANIC CHEMISTRY, 2024, 145
  • [2] Monoamine Oxidase B Inhibitors in Parkinson's Disease
    Dezsi, Livia
    Vecsei, Lzszlo
    CNS & NEUROLOGICAL DISORDERS-DRUG TARGETS, 2017, 16 (04) : 425 - 439
  • [3] Mitochondria, monoamine oxidase B and Parkinson's disease
    Jenner, Peter
    BASAL GANGLIA, 2012, 2 (04) : S3 - S7
  • [4] Platelet monoamine oxidase B and plasma β-phenylethylamine in Parkinson's disease
    Zhou, G
    Miura, Y
    Shoji, H
    Yamada, S
    Matsuishi, T
    JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY, 2001, 70 (02) : 229 - 231
  • [5] Oxazolopyridines and thiazolopyridines as monoamine oxidase B inhibitors for the treatment of Parkinson's disease
    Park, Hye Ri
    Kim, Jiyoon
    Kim, Taekeun
    Jo, Seonmi
    Yeom, Miyoung
    Moon, Bongjin
    Choo, Il Han
    Lee, Jaeick
    Lim, Eun Jeong
    Park, Ki Duk
    Min, Sun-Joon
    Nam, Ghilsoo
    Keum, Gyochang
    Lee, C. Justin
    Choo, Hyunah
    BIOORGANIC & MEDICINAL CHEMISTRY, 2013, 21 (17) : 5480 - 5487
  • [6] Variations in the monoamine oxidase B (MAOB) gene are associated with Parkinson's disease
    Mellick, GD
    Buchanan, DD
    McCann, SJ
    James, KM
    Johnson, AG
    Davis, DR
    Liyou, N
    Chan, D
    Le Couteur, DG
    MOVEMENT DISORDERS, 1999, 14 (02) : 219 - 224
  • [7] Monoamine oxidase-B inhibition in the treatment of Parkinson's disease
    Fernandez, Hubert H.
    Chen, Jack J.
    PHARMACOTHERAPY, 2007, 27 (12): : 174S - 185S
  • [8] Monoamine Oxidase-B (MAO-B) Inhibitors in the Treatment of Alzheimer's and Parkinson's Disease
    Ozdemir, Zeynep
    Alagoz, Mehmet Abdullah
    Bahcecioglu, Omer Faruk
    Gok, Selim
    CURRENT MEDICINAL CHEMISTRY, 2021, 28 (29) : 6045 - 6065
  • [9] The monoamine oxidase B gene GT repeat polymorphism and Parkinson's disease in a Chinese population
    Mellick, GD
    Buchanan, DD
    Silburn, PA
    Chan, DKY
    Le Couteur, DG
    Law, LK
    Woo, J
    Pang, CP
    JOURNAL OF NEUROLOGY, 2000, 247 (01) : 52 - 55
  • [10] No association between Parkinson's disease and monoamine oxidase A and B gene polymorphisms
    Nanko, S
    Ueki, A
    Hattori, M
    NEUROSCIENCE LETTERS, 1996, 204 (1-2) : 125 - 127